Navigation Links
Armenian Hamster Anti-ICOS LEAF™ Monoclonal Antibody, Unconjugated, Clone C398.4A from BioLegend

ProductsArmenian Hamster Anti-ICOS LEAF™ Monoclonal Antibody, Unconjugated, Clone C398.4A from BioLegend
Company BioLegend
Item Armenian Hamster Anti-ICOS LEAF™ Monoclonal Antibody, Unconjugated, Clone C398.4A
Price $280.00
Description LEAF™ Purified anti-human/mouse/rat ICOS
Info BioLegendBioLegend
8395 Camino Santa Fe, Ste. E
San Diego, CA 92121

Customer Service:
(858) 455-9588
(877) 246-5343 Toll-Free USA

Fax Number:
(858) 455-9587

Web Site: http://www.biolegend.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Armenian Hamster Anti-Mouse CD48 Monoclonal Antibody, Biotin Conjugated, Clone HM48-1 from BioLegend
2. Hamster serum from Equitech-Bio
3. Normal Hamster Serum - 50mL from GeneTex
4. Normal Hamster Serum - 500mL from Biomeda Corporation
5. Normal Hamster Serum from Equitech-Bio
6. Syrian Hamster Anti-Mouse Ly-49C / F / I / H Monoclonal Antibody, Biotin Conjugated, Clone 14B11 from BioLegend
7. Mouse Anti-Amodiaquine Monoclonal Antibody, Unconjugated, Clone 6D10 from AntibodyShop A/S
8. Mouse Anti-Protein S Monoclonal Antibody, Unconjugated, Clone HYB 232-02 from Abcam
9. Mouse Anti-Mouse Glutathione S-transferase M1 (GSTM1) Monoclonal Antibody, Unconjugated from Lifespan Biosciences
10. Mouse Anti-Human S-100 alpha/beta chain Monoclonal Antibody, Unconjugated, Clone 8B10 from Santa Cruz Biotechnology, Inc.
11. Anti-S-100 protein, ab heterodimer Monoclonal Antibody, Unconjugated from HyTest Ltd.
Breaking Biology Technology:AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6